---
company: Envista Holdings Corp
ticker: NVST
form: 8-K
filed: 2026-05-06
accession: 0001757073-26-000040
source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000040/
---

# Envista Holdings (NVST) earnings release, May 6, 2026

Envista Holdings Corp (NVST) · Form 8-K, Item 2.02 · Filed 2026-05-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1757073/000175707326000040/)

Envista Reports First Quarter 2026 Results

BREA, Calif., May 6, 2026 /

PRNewswire

/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended April 3, 2026.

“We delivered a good start to 2026, with first quarter results reflecting continued strong execution and progress in support of our strategic priorities,” said Paul Keel, CEO. “We delivered growth across all our major businesses, driven by customer engagement and new product commercialization. Our 9.5% core revenue growth converted to 25% adjusted EBITDA and 50% EPS growth, while also supporting double-digit increases in R&D and Sales & Marketing investment. With momentum continuing, we are reaffirming our full-year guidance and announcing an incremental $300 million share repurchase program.”

First Quarter Financial Highlights

• Sales were $706 million, with core sales growth of 9.5% over the first quarter of 2025.

• GAAP diluted EPS of $0.23 and adjusted diluted EPS of $0.36 (+50% year-on-year)

• GAAP Net Income was $39 million and adjusted EBITDA was $99 million (+25% year-on-year), with an adjusted EBITDA margin of 14.0% (+120 bps year-on-year)

First Quarter Business Highlights

• Growth:

In the context of macro uncertainty, all major businesses delivered positive growth, with 8.4% core growth in our Specialty Products & Technologies segment and 11.5% core growth in our Equipment and Consumables segment.

• Operations:

Ongoing broad-based contributions from the Envista Business System (EBS) supporting 100 bps of Gross Margin and 120 bps of adjusted EBITDA margin expansion.

• People: Continued gains in employee engagement and talent development; 3700 patients served through our charitable Envista Smile Project.

Net Income, EBITDA, and EPS

(in millions, except per share amounts)

:

Cash Flow:

Operating cash flow for the first quarter of 2026 was negative $3 million and free cash flow was negative $16 million, compared to $0 million and negative $5 million in the first quarter of 2025, respectively.

Share Repurchases:

During the quarter ended April 3, 2026, we repurchased 1.6 million shares for approximately $43 million.

At the end of the quarter, we had approximately $41 million remaining repurchase capacity under our stock repurchase program.

On May 5, 2026, our Board of Directors authorized a new stock repurchase program under which we may repurchase an incremental $300 million of our outstanding common stock through December 31, 2029.

Outlook:

We are maintaining the following guidance for the full year 2026:¹

Please note, we do not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.

We will discuss our quarterly results and provide details on our outlook for 2026 during an investor conference call on May 6, 2026, starting at 2:00 P.M. PT. The call and an accompanying slide presentation will be webcast on the "Investors" section of our website, www.envistaco.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of our website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 800-836-8184 within the U.S. or +1 646-357-8785 outside the U.S. a few minutes before 2:00 PM PT and referencing conference ID #51461.

A replay of the conference call will be available shortly after the conclusion of the call. You can access the replay dial-in information on the "Investors" section of our website under the subheading "Events & Presentations." Presentation materials relating to our results have been posted to the "Investors" section of our website under the subheading "Quarterly Earnings".

ABOUT ENVISTA

Envista is a global leader in the dental industry, uniting more than 30 trusted brands—including DEXIS, Kerr, Nobel Biocare, and Ormco—under one mission: partnering with dental professionals to improve patients’ lives. With a heritage of category-defining innovation, our brands have shaped modern dentistry: Nobel Biocare introduced the first dental implant, Ormco is a pioneer in both traditional and digital orthodontics, DEXIS has long been at the forefront of 2D, 3D and intraoral imaging, and Kerr has supported clinicians for over 135 years. Our high-performing culture is underpinned by our CIRCLe Values and the Envista Business System. Guided by these, we deliver a comprehensive portfolio of technologies, consumables, and services that empower clinicians to provide confident, efficient care—today and for the future. Learn more at http://envistaco.com.²

NON-GAAP MEASURES

All "Adjusted" amounts including core sales growth and free cash flow are non-GAAP items. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these non-GAAP measures are included in the attached supplemental schedules. We do not reconcile forward looking non-GAAP measures to the comparable GAAP measures because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions, discontinued products, and any other potential adjustments which would be reflected in any forecasted GAAP measure.

FORWARD-LOOKING STATEMENTS... (truncated)ing interest rates, slower economic growth or recession, international economic, political, legal, compliance and business factors, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations including tariffs or other impositions on imported goods, contractions or growth rates and cyclicality of markets we serve, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, disruptions relating to war (including supply chain disruptions), terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, security breaches or other disruptions of our information technology systems or violations of data privacy laws, security breaches or other disruptions affecting our external information technology contractors, vendors or other service providers, our growing use of artificial intelligence systems to automate processes and analyze data, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, our ability to attract, develop and retain our key personnel, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to impairment charges for our goodwill and intangible assets, changes in accounting standards and subjective assumptions, estimates and judgment by management, currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, the impact of regulation on demand for our products and services, and labor matters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2025 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

CONTACT

Jim Gustafson

Vice President, Investor Relations

Envista Holdings Corporation

200 S. Kraemer Blvd., Building E

Brea, CA 92821

IR@envistaco.com³

## Financial statements

### Income Statement (Three Months Ended — :)

| | Three Months Ended – April 3, 2026 | Three Months Ended – March 28, 2025 |
|---|---:|---:|
| GAAP Net Income | 39 | 18 |
| Adjusted Net Income | 60 | 42 |
| Adjusted EBITDA | 99 | 79 |
| GAAP Diluted Earnings Per Share | 0.23 | 0.1 |
| Adjusted Diluted Earnings Per Share | 0.36 | 0.24 |

### Income Statement (We are maintaining the following guidance for the full year 2026:)

| | 2026 Guidance |
|---|---:|
| Core Sales Growth | 2% to 4% |
| Adjusted EBITDA Growth | 7% to 13% |
| Adjusted Diluted Earnings Per Share | $1.35 to $1.45 |
| Free Cash Conversion | ~100% |

### Income Statement (Three Months Ended — ($ and shares in millions, except per share amounts))

| | Three Months Ended – April 3, 2026 | Three Months Ended – March 28, 2025 |
|---|---:|---:|
| Sales | 705.5 | 616.9 |
| Cost of sales | 315.4 | 280.9 |
| Gross profit | 390.1 | 336 |
| Operating expenses: | Selling, general and administrative | 297.6 | 271.7 |
| Operating expenses: | Research and development | 30 | 25.3 |
| Operating expenses: | Operating profit | 62.5 | 39 |
| Nonoperating (expense) income: | Other expense, net | -2.9 | -0.7 |
| Nonoperating (expense) income: | Interest expense, net | -7.4 | -9.3 |
| Nonoperating (expense) income: | Income before income taxes | 52.2 | 29 |
| Nonoperating (expense) income: | Income tax expense | 13.5 | 11 |
| Nonoperating (expense) income: | Net income | 38.7 | 18 |
| Earnings per share: | Earnings - basic | 0.24 | 0.1 |
| Earnings per share: | Earnings - diluted | 0.23 | 0.1 |
| Average common stock and common equivalent shares outstanding: | Basic | 163.9 | 172.4 |
| Average common stock and common equivalent shares outstanding: | Diluted | 166.4 | 173.6 |

### Income Statement (Three Months Ended — ($ in millions, except per share amounts))

| | Three Months Ended – April 3, 2026 – GAAP | Three Months Ended – March 28, 2025 – GAAP |
|---|---:|---:|
| Gross Profit | 390.1 | 336 |
| Operating Profit | 62.5 | 39 |
| Net Income | 38.7 | 18 |
| Diluted Earnings Per Share | 0.23 | 0.1 |
| Operating Cash Flow | -3.3 | 0.3 |

### Income Statement (($ in millions, except per share amounts))

| | NON-GAAP * – Three Months Ended – April 3, 2026 | NON-GAAP * – Three Months Ended – March 28, 2025 |
|---|---:|---:|
| Adjusted Gross Profit | 393.6 | 338.3 |
| Adjusted Operating Profit | 89.4 | 70.6 |
| Adjusted Net Income | 60 | 41.5 |
| Adjusted Diluted EPS | 0.36 | 0.24 |
| Adjusted EBITDA | 98.9 | 79 |
| Free Cash Flow | -15.7 | -5.1 |

### Income Statement (Three Months Ended — Adjusted Gross Profit and Adjusted Gross Margin)

| | Three Months Ended – April 3, 2026 | Three Months Ended – March 28, 2025 |
|---|---:|---:|
| Gross Profit | 390.1 | 336 |
| Restructuring costs and asset impairments A | 3.1 | 1.9 |
| Fair value adjustment of acquisition-related inventory B | 0.4 | 0.4 |
| Adjusted Gross Profit | 393.6 | 338.3 |
| Gross Margin (Gross Profit / Sales) | 55.3 | 54.5 |
| Adjusted Gross Margin (Adjusted Gross Profit / Sales) | 55.8 | 54.8 |

### Income Statement (Three Months Ended — Adjusted Diluted Earnings Per Share)

| | Three Months Ended – April 3, 2026 | Three Months Ended – March 28, 2025 |
|---|---:|---:|
| Diluted Earnings Per Share | 0.23 | 0.1 |
| Amortization of acquisition-related and other intangible assets | 0.11 | 0.11 |
| Restructuring costs and asset impairments A | 0.05 | 0.07 |
| Litigation settlement C |  | 0.01 |
| Loss on equity investments E | 0.01 |  |
| Tax effect of adjustments reflected above F | -0.04 | -0.05 |
| Adjusted Diluted Earnings Per Share | 0.36 | 0.24 |

### Income Statement (Three Months Ended — Adjusted EBITDA)

| | Three Months Ended – April 3, 2026 | Three Months Ended – March 28, 2025 |
|---|---:|---:|
| Net Income | 38.7 | 18 |
| Interest expense, net | 7.4 | 9.3 |
| Income tax expense | 13.5 | 11 |
| Depreciation | 10.4 | 9.1 |
| Amortization of acquisition-related and other intangible assets | 18.8 | 18.8 |
| Restructuring costs and asset impairments A | 7.4 | 11.4 |
| Fair value adjustment of acquisition-related inventory B | 0.4 | 0.4 |
| Litigation settlement C |  | 0.8 |
| Acquisition-related expenses D | 0.3 | 0.2 |
| Loss on equity investments E | 2 |  |
| Adjusted EBITDA | 98.9 | 79 |
| Adjusted EBITDA as a % of Sales | 14 | 12.8 |

### Balance Sheet (($ in millions, except share amounts))

| | As of – April 3, 2026 | As of – December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 1,082.8 | 1,211.7 |
| Current assets: | Trade accounts receivable, less allowance for credit losses of $23.7 and $22.5, respectively | 436.6 | 429.6 |
| Current assets: | Inventories, net | 300.3 | 288.1 |
| Current assets: | Prepaid expenses and other current assets | 99.4 | 97.2 |
| Current assets: | Total current assets | 1,919.1 | 2,026.6 |
| Current assets: | Property, plant and equipment, net | 298.7 | 296.8 |
| Current assets: | Operating lease right-of-use assets | 143.6 | 142.1 |
| Current assets: | Other long-term assets | 223.8 | 228.1 |
| Current assets: | Goodwill | 2,359.8 | 2,358.2 |
| Current assets: | Other intangible assets, net | 633 | 627.2 |
| Current assets: | Total assets | 5,578 | 5,679 |
| Current liabilities: | Trade accounts payable | 170 | 191.6 |
| Current liabilities: | Accrued expenses and other liabilities | 577.9 | 622 |
| Current liabilities: | Operating lease liabilities | 38.7 | 39 |
| Current liabilities: | Total current liabilities | 786.6 | 852.6 |
| Current liabilities: | Operating lease liabilities | 111.4 | 110.4 |
| Current liabilities: | Other long-term liabilities | 161.4 | 161.4 |
| Current liabilities: | Long-term debt | 1,439.1 | 1,448.3 |
| Stockholders’ equity: | Common stock, $0.01 par value, 500.0 million shares authorized; 176.2 million shares issued and 162.9 million shares outstanding at April 3, 2026; 175.4 million shares issued and 163.8 million shares outstanding at December 31, 2025 | 1.8 | 1.8 |
| Stockholders’ equity: | Treasury stock at cost; 13.3 million shares and 11.6 million shares at April 3, 2026 and December 31, 2025, respectively | -273.5 | -224.5 |
| Stockholders’ equity: | Additional paid-in capital | 3,896 | 3,882.6 |
| Stockholders’ equity: | Accumulated deficit | -401.7 | -440.4 |
| Stockholders’ equity: | Accumulated other comprehensive loss | -143.1 | -113.2 |
| Stockholders’ equity: | Total stockholders’ equity | 3,079.5 | 3,106.3 |

### Cash Flow (Three Months Ended — ($ in millions))

| | Three Months Ended – April 3, 2026 | Three Months Ended – March 28, 2025 |
|---|---:|---:|
| Cash flows from operating activities: | Net income | 38.7 | 18 |
| Noncash items: | Depreciation | 10.4 | 9.1 |
| Noncash items: | Amortization | 18.8 | 18.8 |
| Noncash items: | Allowance for credit losses | 4.4 | 1.3 |
| Noncash items: | Stock-based compensation expense | 10.2 | 7.1 |
| Noncash items: | Loss on investments in rabbi trust, net | 0.9 | 0.6 |
| Noncash items: | Loss on equity investments | 2 |  |
| Noncash items: | Loss on sale of property, plant and equipment | 0.1 |  |
| Noncash items: | Restructuring charges |  | 0.2 |
| Noncash items: | Non-cash operating lease costs | 9.1 | 8.4 |
| Noncash items: | Amortization of debt discount and issuance costs | 1 | 1.1 |
| Noncash items: | Change in trade accounts receivable | -13.3 | -21.3 |
| Noncash items: | Change in inventories | -9.6 | -10.1 |
| Noncash items: | Change in trade accounts payable | -21.4 | -15.1 |
| Noncash items: | Change in prepaid expenses and other assets | -3.1 | -7.8 |
| Noncash items: | Change in accrued expenses and other liabilities | -39.8 | 0.8 |
| Noncash items: | Change in operating lease liabilities | -11.7 | -10.8 |
| Noncash items: | Net cash (used in) provided by operating activities | -3.3 | 0.3 |
| Cash flows from investing activities: | Payments for additions to property, plant and equipment | -12.5 | -5.9 |
| Cash flows from investing activities: | Purchases of investments held in rabbi trust | -3.4 | -0.7 |
| Cash flows from investing activities: | Proceeds from sale of investments held in rabbi trust | 0.5 | 0.7 |
| Cash flows from investing activities: | Proceeds from sales of property, plant and equipment | 0.1 | 0.5 |
| Cash flows from investing activities: | Acquisitions, net of cash acquired | -54.4 | -3.6 |
| Cash flows from investing activities: | All other investing activities, net | 0.8 | 0.2 |
| Cash flows from investing activities: | Net cash used in investing activities | -68.9 | -8.8 |
| Cash flows from financing activities: | Proceeds from stock option exercises | 3.5 | 0.8 |
| Cash flows from financing activities: | Cash paid for treasury stock under the stock repurchase program | -42.7 | -14.6 |
| Cash flows from financing activities: | Treasury stock purchases related to tax withholding on equity awards | -6 | -3.8 |
| Cash flows from financing activities: | All other financing activities | -0.4 |  |
| Cash flows from financing activities: | Net cash used in financing activities | -45.6 | -17.6 |
| Cash flows from financing activities: | Effect of exchange rate changes on cash and cash equivalents | -11.1 | 34.3 |
| Cash flows from financing activities: | Net change in cash and cash equivalents | -128.9 | 8.2 |
| Cash flows from financing activities: | Beginning balance of cash and cash equivalents | 1,211.7 | 1,069.1 |
| Cash flows from financing activities: | Ending balance of cash and cash equivalents | 1,082.8 | 1,077.3 |

### Cash Flow (Three Months Ended — Reconciliation of Operating Cash Flows to Free Cash Flow)

| | Three Months Ended – April 3, 2026 | Three Months Ended – March 28, 2025 |
|---|---:|---:|
| Net operating cash (used in) provided by operating activities | -3.3 | 0.3 |
| Less: payments for additions to property, plant and equipment (capital expenditures) | -12.5 | -5.9 |
| Plus: proceeds from sales of property, plant and equipment | 0.1 | 0.5 |
| Free Cash Flow (FCF) | -15.7 | -5.1 |
| FCF to Adjusted Net Income Conversion Ratio | -26.2 | -12.3 |
